Results 11 to 20 of about 542,975 (311)
Cells, 2022 Current research proves that immune dysregulation is a common feature of coronavirus disease 2019 (COVID-19), and immune exhaustion is associated with increased disease mortality.
Paulina Niedźwiedzka-Rystwej +8 more
doaj +3 more sources
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
Chinese Medical Journal, 2017 Objective: Sepsis remains a leading cause of death in many Intensive Care Units worldwide. Immunosuppression has been a primary focus of sepsis research as a key pathophysiological mechanism.
Qiang Liu, Chun-Sheng Li
doaj +3 more sources
Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer [PDF]
The Oncologist, 2018 Abstract Prostate cancer is the second leading cause of cancer death in American men. Despite the common nature of this disease, there is a poor understanding of biomarkers that predict responsiveness to immunotherapeutic agents such as the programmed death-1 (PD-1) and programmed death-ligand 1 (PD ...
Manogue, Charlotte +5 more
openaire +2 more sources
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer [PDF]
Clinical Cancer Research, 2007 AbstractPurpose: The programmed death-1 ligand/programmed death-1 (PD-L/PD-1) pathway has been recently suggested to play a pivotal role in the immune evasion of tumors from host immune system. In this study, we tried to reveal the clinical importance and therapeutic potential of the PD-L/PD-1 pathway in pancreatic cancer, which is one of the most ...
Takeo, Nomi +10 more
openaire +2 more sources
Targeting the programmed death-1 pathway in lymphoid neoplasms [PDF]
Cancer Treatment Reviews, 2017 Programmed death-1 (PD-1) is a co-inhibitory molecule and is seen in CD4+ and CD8+ T cells. Upon binding to its ligands, programmed death ligand-1 (PD-L1) and -2 (PD-L2), PD-1 negatively regulates interleukin 2 (IL-2) production and T cell proliferation.
Chi Young, Ok, Ken H, Young
openaire +2 more sources
Journal of Receptor, Ligand and Channel Research, 2014 Kurt A Schalper,1 Vyshak Alva Venur,2 Vamsidhar Velcheti2 1Department of Pathology, Yale University, New Haven, CT, 2Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH, USA Abstract: Over the past few years, the functional modulation of immune-checkpoint pathways using monoclonal antibodies has emerged as a promising anticancer therapeutic strategy.
Vamsidhar Velcheti +2 more
openaire +4 more sources
The Role of Programmed Death-1 in Type 1 Diabetes
Current Diabetes Reports, 2021 Programmed death-1 (PD-1) is an inhibitory receptor that controls T and B cell proliferation and function through interacting with its ligand PD-L1 or PD-L2. PD-1/PD-L1 blockade reboots anti-tumor immunity and is currently used to treat > 15 different types of cancer. However, the response rate is not at 100% and some patients relapse.
Christopher G. Tucker +3 more
openaire +3 more sources
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]
, 2015 Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core +2 more sources
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
Endocrine Connections, 2018 Background: Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy.
Jaafar Jaafar +3 more
doaj +1 more source
Diagnostics, 2022 Sepsis is a series of life-threatening organ dysfunction caused by an impaired host response to infection. A large number of molecular studies of sepsis have revealed complex interactions between infectious agents and hosts that result in heterogeneous ...
Mutiara Indah Sari, Syafruddin Ilyas
doaj +1 more source